All In Biotech

Drug Trial Radar · NCT05764733

Bone, Exercise, Alendronate, and Caloric Restriction

The Bone, Exercise, Alendronate, and Caloric Restriction Trial

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jun 8, 2023

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Wake Forest University Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight. Participation in this research will involve up to nine assessment visits and last up to two years.

Conditions

  • Bone Loss

Interventions

  • BisphosphonateDrug

    Medicine used to treat bone problems, called osteopenia or osteoporosis.

  • Resistance Training/Bone-Loading ExerciseBehavioral

    Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.

  • PlaceboOther

    Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in total hip areal bone mineral density (aBMD)Time frame: from baseline through month 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.